Prevalence of anti-SARS-CoV-2 antibodies and some related factors in asymptomatic COVID-19 patients in hospital, Dak Lak, 11/2021-3/2022

Abstract

A study aims to describe status antibodies against SARS-CoV-2 and some related factors in asymptomatic COVID-19 patients in Dak Lak province, 11/2021 - 3/2022. In this study, Electrochemiluminescence Immunoassay (ECLIA) was used to estimate the anti-SARS-CoV-2 antibodies against receptor binding protein (RBD) in human serum. The results showed that among 248 participants, the seropositivity rate for SARSCOV-2 antibodies at day 7 (D7) and day 14 (D14) after infection were 86.7% and 91.5%; respectively. Of which, the seroprevalence of vaccinated individuals at D7 and D14 were 92.1% and 96.3% compared to only 50.0% and 55.6% found in non-vaccinated individuals. A signigficant difference in seroprevalence between vaccinated and non-vaccinated groups was observed (p < 0.01). The seropositivity prevalence for SARS-CoV-2 antibodies in vaccinated people who received single dose at day 7 (90.3%) was significant lower than those with two doses (100%) (p < 0.05). However, by day 14, there was a similar in seropositivity between groups with single and two doses (p > 0.05). No significant difference in seropositivity prevalence was found according to gender, age groups, ethinicity, high white blood cell count (WBC) and chest CT scans. The results are providing more scientific findings of the need for increased COVID-19 vaccination to maintain and improve levels of Anti-SARSCoV-2 antibodies.